MPC Inhibitor Combination Therapy for TKI-Resistant CML Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tyrosine kinase inhibitors (TKIs) fail to eradicate leukemic stem cells (LSCs) in chronic myeloid leukemia (CML), leading to treatment resistance and disease progression, necessitating new therapeutic strategies to target and sensitize LSCs.
Innovation Solution
Inhibiting mitochondrial pyruvate transport using compounds that target the mitochondrial pyruvate carrier (MPC) to directly inhibit LSC expansion and sensitize them to TKIs, combined with BCR-ABL kinase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If tyrosine kinase inhibitors (TKIs) are used to treat CML, then patient survival is prolonged, but leukemic stem cells (LSCs) remain resistant and disease progresses
Solution Approach 1:
The treatment approach is segmented into two distinct components: TKIs that target BCR-ABL signaling in bulk leukemic cells, and MPC inhibitors that specifically target the metabolic pathways of leukemic stem cells. This segmentation allows each agent to address different aspects of the disease, with the MPC inhibitor specifically eliminating the TKI-resistant LSC population that would otherwise cause relapse
Solution Approach 2:
The MPC inhibitor acts as an intermediary agent that bridges the gap in TKI therapy by targeting a different metabolic vulnerability (mitochondrial pyruvate transport) in LSCs. This intermediary approach allows the combination therapy to overcome TKI resistance without requiring changes to the TKI mechanism itself
2Duration of action of moving object
If TKI treatment is continued to prevent disease progression, then more patients survive longer, but the prevalence of CML increases
Solution Approach 1:
The MPC inhibitor extracts and eliminates the persistent LSC population that serves as a reservoir for disease recurrence. By specifically targeting and removing these stem cells through metabolic inhibition, the therapy achieves deeper molecular responses and enables treatment discontinuation in more patients, thereby reducing long-term disease prevalence
3Reliability
If MPC inhibitors are used to target LSCs, then LSC expansion is inhibited and TKI sensitivity is enhanced, but treatment complexity increases
Solution Approach 1:
The therapy merges TKI and MPC inhibitor into a unified combination regimen that targets both bulk leukemic cells and LSCs. This merging creates a synergistic effect where the MPC inhibitor sensitizes LSCs to TKIs while independently inhibiting LSC expansion, achieving comprehensive disease control through a coordinated dual-mechanism approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively reduces LSC population, enhances TKI sensitivity, and prolongs treatment-free remission in CML patients.
Implementation Method 1
Pyruvate transport into mitochondria is mediated by the mitochondrial pyruvate carrier (MPC). Thus an agent which inhibits mitochondrial pyruvate transport may be designated as an MPC inhibitor.
Data Source
AI summary
The invention relates to the treatment of chronic myeloid leukemia (CML). In particular it relates to the treatment of CML with inhibitors of mitochondrial pyruvate transport, which are able to target leukemic stem cells (LSCs) which are resistant to therapy with tyrosine kinase inhibitors (TKIs). Combination therapies with BCR-ABL kinase inhibitors are also described.